An interventional study of Progressive Pressure Support Reduction (IRT-PS) and Standard ICU Care in Respiratory Muscle Weakness, Mechanical Ventilation Weaning and Physiotherapy, sponsored by University of Santiago de Compostela. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by University of Santiago de Compostela · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Muscle Weakness with a site in Spain — 3 open to participants now, 5 under way, none of them phase 3. Muscle Weakness · Spain.
Among the 27 studies in Muscle Weakness with a site in Spain, this one is the 10th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 15 with no phase, and was the 26th registered.
478 studies on the registry are indexed under Muscle Weakness; 72 are open to participants now.
Browse Muscle Weakness studies →3 of the 27 studies in Muscle Weakness with a site in Spain are open now. Recruiting first, the newest first:
Inés Llamas-Ramos · Sites in Spain
Ages 18–70
Pharming Technologies B.V. · Sites in Spain, United States, Australia and 8 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 52 Muscle Weakness studies recruiting now, 25 (48%) set no upper age limit and 20 (38%) stop at 75 or younger; 5 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 44 across 364 interventional studies indexed under Muscle Weakness.
Median enrollment 60 across the 19 interventional studies, 50 across the 8 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 27 have an industry lead sponsor. The 10 most frequent:
University of Santiago de Compostela is the lead sponsor of 60 studies on the registry; 12 are open to participants now.
University of Santiago de Compostela has 1 study filed under Muscle Weakness — fewer than ten, so there is no comparison to draw.
2 of the studies in Muscle Weakness with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07745712ABLE Human Motion S.L.Clinical Investigation to Validate the Safety and Performance of the ABLE Kids Device in Pediatric Patients With Neurological Gait Disorders in a Clinical Setting | 2026-12-31 |
| NCT05650229Pharming Technologies B.V.Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Muscle Weakness with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Mechanical ventilation causes rapid diaphragm muscle atrophy, detectable within 18 hours of ventilator support, which is a major contributor to weaning failure and prolonged ICU stay.
This randomized controlled trial tests whether a physiotherapist-guided inspiratory endurance training program - achieved by progressively reducing pressure support (PS) levels on the ventilator - can preserve or improve inspiratory muscle strength and diaphragm structure in critically ill adults on mechanical ventilation, compared to standard ICU care.
Participants will be randomly assigned to one of two groups. The intervention group will receive twice-daily training sessions (weekdays only) in which the physiotherapist gradually reduces PS by up to 50% of the baseline level, causing the patient to breathe with greater muscular effort - equivalent to progressive endurance exercise for the diaphragm. The control group will receive standard weaning care as directed by the attending intensivist.
The primary outcome is maximal inspiratory pressure (PImax) at day 7. Secondary outcomes include diaphragm thickening fraction measured by ultrasound, time to successful extubation, weaning success rate, and mortality.
All measurements are performed by the ICU physician (blinded to group allocation) using airway occlusion maneuvers recorded on the ventilator and diaphragm ultrasound, following a standardized protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Physiotherapist-guided inspiratory endurance training by progressive pressure support reduction (25-50% of baseline PS), 1-3 sets of 5-15 minutes, twice daily on weekdays, for up to 14 days or until extubation. Target: Borg CR10 score 3-5. P0.1 monitored continuously; sessions stopped if P0.1 \> 4 cmH2O sustained \> 2 minutes.
Behavioral: Progressive Pressure Support Reduction (IRT-PS)
Conventional weaning as directed by the attending intensivist, without a structured inspiratory muscle training program. Conventional physiotherapy (early mobilization, chest physiotherapy) is permitted in both groups.
Other: Standard ICU Care
Progressive reduction of pressure support (PS) during ventilator-assisted breathing, performed by a physiotherapist twice daily (weekdays only). Sessions consist of 1-3 sets of 5-15 minutes with 2-minute rest intervals at baseline PS. PS is reduced by 25% initially up to a maximum of 50% of baseline (minimum 5 cmH2O) for PS ≥10 cmH2O; by 1-2 cmH2O for PS 5-9 cmH2O; and by 1 cmH2O down to 0 cmH2O for PS \<5 cmH2O. Target perceived exertion: Borg CR10 3-5. P0.1 monitored continuously; session stopped if P0.1 \>4 cmH2O sustained \>2 minutes (Goligher et al. criteria). Safety stop criteria: RR \>35 rpm, SpO2 \<90%, HR \>120 bpm.
Conventional weaning managed by the attending intensivist according to standard clinical practice, without a structured inspiratory muscle training protocol. Conventional physiotherapy (early mobilization, chest physiotherapy) permitted in both groups.
Maximal Inspiratory Pressure (PImax)
Measured by manual airway occlusion at end-expiration with pressure curve recorded on the ventilator. Standardized verbal instruction given to the patient. Best of 3 valid maneuvers recorded. Performed by the ICU physician blinded to group allocation.
Time frame: Day 7 from randomization
Diaphragm Thickening Fraction (DTF)
measured by ultrasound (linear probe 7-15 MHz, zone of apposition, M-mode, average of 3 cycles). Performed by ICU physician per standardized protocol.
Time frame: Days 0, 3, 7 and 14 from randomization
P0.1 (Airway Occlusion Pressure at 100ms
respiratory drive indicator, read directly from ventilator display
Time frame: Baseline and days 3, 7 and 14; and at start, mid and end of each training session (intervention group)
Time to Successful Extubation
hours from randomization to extubation without reintubation within 48 hours
Time frame: From randomization until extubation, up to 14 days
Weaning Success Rate
proportion of patients extubated without reintubation within 48 hours
Time frame: Days 7 and 14 from randomization
Sustained Pressure Support Reduction
difference in cmH2O between baseline PS at Day 0 and Day 7
Time frame: days 1, 3, 5 and 7 from randomization
Total Days on Mechanical Ventilation
Time frame: From randomization until ICU discharge, up to 30 days
ICU Mortality
Time frame: At the time of ICU discharge (up to 24 weeks)
30-day Mortality
Time frame: Day 30 from randomization
ICU Readmission at 30 days
Time frame: Day 30 from randomization
Borg CR10 Score during training session
perceived respiratory exertion (0-10)
Time frame: Periprocedural (from the start of the session until 30 minutes post-intervention)
Adverse events during training sessions
episodes of RR \>35, SpO2 \<90%, HR \>120 bpm
Time frame: Periprocedural (from the start of the session until 30 minutes post-intervention)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.
Of 200 non-industry interventional studies with no phase under Muscle Weakness, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 14 months is above that.
Counting every sponsor, half of 212 studies reached it within 12 months; a quarter within 5 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Santiago de Compostela